A case of multiple endocrine neoplasia type II accompanied by thyroid medullary carcinoma and pheochromocytomas expressing corticotropin-releasing factor and urocortins

American Journal of the Medical Sciences

Volumn 335, Issue 5, 2008, Pages 398-402

  Kageyama, Kazunori ^a   Sakihara, Satoru ^a   Yamashita, Maki ^a   Takahashi, Kazuhiro ^b   Kawashima, Shoko ^a   Tanabe, Jutaro ^a   Tsutaya, Shoji ^c   Yasujima, Minoru ^a   Suda, Toshihiro ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c HIROSAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Corticotropin releasing factor; MEN; Pheochromocytoma; Thyroid carcinoma; Urocortin

Indexed keywords

(3 IODOBENZYL)GUANIDINE; ADRENALIN; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; DEXAMETHASONE; HYDROCORTISONE; IODINE 131; NORADRENALIN; UROCORTIN I; UROCORTIN III; UROCORTIN;

ADRENAL GLAND; ADRENAL TUMOR; ADULT; ARTICLE; CASE REPORT; CIRCADIAN RHYTHM; CONTROLLED STUDY; CUSHING DISEASE; ECHOGRAPHY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HORMONE RELEASE; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IMPAIRED GLUCOSE TOLERANCE; MULTIPLE ENDOCRINE NEOPLASIA; MULTIPLE ENDOCRINE NEOPLASIA TYPE II; NUCLEAR MAGNETIC RESONANCE IMAGING; PHEOCHROMOCYTOMA; PROTEIN EXPRESSION; RET GENE; SCINTIGRAPHY; THYROID GLAND; THYROID MEDULLARY CARCINOMA; TUMOR GENE; BLOOD; CHEMISTRY; MEDULLARY CARCINOMA; PATHOLOGY; SIPPLE SYNDROME; THYROID TUMOR;

ADRENAL GLAND NEOPLASMS; ADRENOCORTICOTROPIC HORMONE; ADULT; CARCINOMA, MEDULLARY; CORTICOTROPIN-RELEASING HORMONE; FEMALE; HUMANS; HYDROCORTISONE; IMMUNOHISTOCHEMISTRY; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; PHEOCHROMOCYTOMA; THYROID NEOPLASMS; UROCORTINS;

EID: 45549089975     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31815200f8     Document Type: Article

References (42)

1. Vaughan J, Donaldson C, Bittencourt J. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 1995;378:287-92.
2. Hsu SY, Hsueh AJ. Human stresscopin and stresscopin- related peptide are selective ligands for the type 2 cortico- tropin-releasing hormone receptor. Nat Med 2001;7:605-611.
3. Reyes TM, Lewis K, Perrin MH. Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci USA 2001;98:2843-8.
4. Lewis K, Li C, Perrin MH. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci USA 2001;98:7570-5.
5. Vale W, Spiess J, Rivier C. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 1981;213:1394-7.
6. Iino K, Sasano H, Oki Y. Urocortin expression in human pituitary gland and pituitary adenoma. J Clin Endocrinol Metab 1997;82:3842-50.
7. Takahashi K, Totsune K, Sone M. Regional distribution of urocortin-like immunoreactivity and expression of urocortin mRNA in the human brain. Peptides 1998;19:643-7.
8. Muramatsu Y, Fukushima K, Iino K. Urocortin and corticotropin-releasing factor receptor expression in the human colonic mucosa. Peptides 2000;21:1799-809.
9. Muramatsu Y, Sugino N, Suzuki T. Urocortin and cortico- tropin-releasing factor receptor expression in normal cycling human ovaries. J Clin Endocrinol Metab 2001;86:1362-9.
10. Kimura Y, Takahashi K, Totsune K. Expression of urocor- tin and corticotropin-releasing factor receptor subtypes in the human heart. J Clin Endocrinol Metab 2002;87:340-6.
11. Takahashi K, Totsune K, Murakami O. Expression of urocortin III/stresscopin in human heart and kidney. J Clin Endocrinol Metab 2004;89:1897-903.
12. Saruta M, Takahashi K, Suzuki T. Urocortin 3/stresscopin in human colon: possible modulators of gastrointestinal function during stressful conditions. Peptides 2005;26:1196-2106.
13. Florio P, Torres PB, Torricelli M. Human endometrium expresses urocortin II and III messenger RNA and peptides. Fertil Steril 2006;86:1766-70.
14. Kageyama K, Bradbury MJ, Zhao L. Urocortin messenger ribonucleic acid: tissue distribution in the rat and regulation in thymus by lipopolysaccharide and glucocorticoids. Endocrinology 1999;140:5651-8.
15. Suda T, Kageyama K, Sakihara S. Physiological roles of urocortins, human homologues of fish urotensin I, and their receptors. Peptides 2004;25:1689-701.
16. Chang CP, Pearse RI, O'Connell S. Identification of a seven transmembrane helix receptor for corticotropin-releasing factor and sauvagine in mammalian brain. Neuron 1993; 11:1187-95.
17. Chen R, Lewis KA, Perrin MH. Expression cloning of a human corticotropin-releasing-factor receptor. Proc Natl Acad Sci USA 1993;90:8967-71.
18. Vita N, Laurent P, Lefort S. Primary structure and functional expression of mouse pituitary and human brain corticotrophin releasing factor receptors. FEBS Lett 1993;335:1-5.
19. Lovenberg TW, Liaw CW, Grigoriadis DE. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci USA 1995;92:836-40.
20. Perrin M, Donaldson C, Chen R. Identification ofa second CRF receptor gene and characterization of a cDNA expressed in heart. Proc Natl Acad Sci USA 1995;92:2969-73.
21. Stenzel P, Kesterson R, Yeung W. Identification of a novel murine receptor for corticotropin-releasing hormone expressed in the heart. Mol Endocrinol 1995;9:637-45.
22. Kishimoto T, Pearse RV II, Lin CR. A sauvagine/corticotropin- releasing factor receptor expressed in heart and skeletal muscle. Proc Natl Acad Sci USA 1995;92:1108-12.
23. Vale W, Vaughan J, Perrin MH. Corticotropin-releasing factor (CRF) family ligands and their receptors. Endocrinologist 1997;7:3S-9S.
24. Kageyama K, Furukawa K-I, Miki I. Vasodilative effects of urocortin II via protein kinase A and a mitogen-activated protein kinase in rat thoracic aorta. J Cardiovasc Pharmacol 2003;42:561-5.
25. Terui K, Higashiyama A, Horiba N. Coronary vasodilation and positive inotropism by urocortin in the isolated rat heart. J Endocrinol 2001;169:177-83.
26. Takahashi K, Totsune K, Murakami O. Urocortins as cardiovascular peptides. Peptides 2004;25:1723-31.
27. Rademaker MT, Cameron VA, Charles CJ. Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure. Circulation 2005;112:3624-32.
28. Suda T, Tomori N, Tozawa F. Immunoreactive cortico- tropin and corticotropin-releasing factor in human hypothal- amus, adrenal, lung cancer, and pheochromocytoma. J Clin Endocrinol Metab 1984;58:919-24.
29. Willenberg HS, Bornstein SR, Hiroi N. Effects of a novel corticotropin-releasing-hormone receptor type I antagonist on human adrenal function. Mol Psychiatry 2000;5:137-41.
30. Fukuda T, Takahashi K, Suzuki T. Urocortin 1, urocortin 3/stresscopin, and corticotropin-releasing factor receptors in human adrenal and its disorders. J Clin Endocrinol Metab 2005;90:4671-8.
31. Punales MK, Graf H, Gross JL. RET codon 634 mutations in multiple endocrine neoplasia type 2: variable clinical features and clinical outcome. J Clin Endocrinol Metab 2003;88:2644-9.
32. Jindrichova S, Kodet R, Krskova L. The newly detected mutations in the RET proto-oncogene in exon 16 as a cause of sporadic medullary thyroid carcinoma. J Mol Med 2003;81: 819-23.
33. Murakami O, Takahashi K, Sone M. An ACTH-secreting bronchial carcinoid: presence of corticotropin-releasing hormone, neuropeptide Y and endothelin-1 in the tumor tissue. Acta Endocrinol (Copenh) 1993;128:192-6.
34. Gagel RF. Multiple endocrine neoplasia. In: Wilson JD, Foster DW, Kronenberg HM, et al, editors. Williams' textbook of endocrinology, 9th ed. Philadelphia: WB Saunders; 1998. p. 1628-49.
35. de Groot JW, Links TP, Plukker JT. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev. 2006;27:535-60.
36. Suda T. Adrenal preclinical Cushing's syndrome. JMAJ 2002;45:172-4.
37. Venihaki M, Ain K, Dermitzaki E. KAT45, a noradrenergic human pheochromocytoma cell line producing corticotropin- releasing hormone. Endocrinology 1998;139:713-22.
38. Takahashi K, Totsune K, Saruta M. Expression ofurocortin 3/stresscopin in human adrenal glands and adrenal tumors. Peptides 2006;27:178-82.
39. Evans CJ, Erdelyi E, Weber E. Identification of pro-opiomelanocortin-derived peptides in the human adrenal medulla. Science 1983;221:957-60.
40. Asaba K, Makino S, Hashimoto K. Effect of urocortin on ACTH secretion from rat anterior pituitary in vitro and in vivo: comparison with corticotropin-releasing hormone. Brain Res 1998;806:95-103.
41. Lubomirov L, Gagov H, Petkova-Kirova P. Urocortin relaxes rat tail arteries by a PKA-mediated reduction of the sensitivity of the contractile apparatus for calcium. Br J Pharmacol 2001;134:1564-70.
42. Kageyama K, Hanada K, Nigawara T. Urocortin induces interleukin-6 gene expression via cyclooxygenase-2 activity in aortic smooth muscle cells. Endocrinology 2006;147: 4454-62.